Guardant Health price target raised to $65 from $60 at BTIG

BTIG raised the firm’s price target on Guardant Health (GH) to $65 from $60 and keeps a Buy rating on the shares. The company delivered another clean beat and raise quarter, and on the call, GH highlighted that its core G360 growth accelerated again in Q1, its Reveal MRD test is its fastest growing test, and management emphasized the impact that its new Guardant360 Tissue CGP test can have on the market, stating that there is no reason why that newer test can not obtain similar market share as its marketing-leading G360 test, the analyst tells investors in a research note.